Fitness News
Asthma Allergy News
Diabetes News
Women's Health News
 > Men's Health News

Personal Archive
My Account

About Us
Advertise With Us
Feed Your Site
Contact Us

Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

Methylprednisolone Shot-Linked Fungal Infections Investigated
Eighty-one percent of patients without peripheral-joint infection had CNS infection

WEDNESDAY, Oct. 23 (HealthDay News) -- For patients who received epidural, paraspinal, or joint infections with contaminated lots of methylprednisolone acetate, infections caused by the outbreak associated pathogen Exserohilum rostratum result in a spectrum of clinical disease, according to a study published in the Oct. 24 issue of the New England Journal of Medicine.

Tom M. Chiller, M.D., M.P.H.&T.M., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues reviewed the medical records for outbreak cases reported to the CDC before Nov. 19, 2012. Polymerase chain reaction assays and immunohistochemical testing were performed to identify pathogens.

The researchers found that 81 percent of the 328 patients without peripheral-joint infection who were included in the investigation had central nervous system (CNS) infection, and 19 percent had non-CNS infections. Of the 268 patients for whom samples were available, 36 percent had laboratory evidence of E. rostratum. For patients with CNS infections, there was a significant correlation between strokes and increased severity of abnormalities in cerebrospinal fluid. Non-CNS infections developed in patients with and without meningitis and were more frequent with a longer interval from last injection to diagnosis.

"Ongoing analyses of epidemiologic and clinical data from this fungal outbreak may further our knowledge about the pathophysiology of exserohilum infection and contribute to a better understanding of treatment and diagnostic options for iatrogenic CNS and paraspinal fungal infection," the authors write.

Full Text

Copyright © 2013 HealthDay. All rights reserved.

Back to Top Stories